U.S. Markets closed

VWR Corp Acquires EPL Archives, Improves Customer Service

Zacks Equity Research

Radnor, PA-based VWR Corporation VWR – a global provider of products, services and solutions to laboratory and production facilities – recently acquired the international biorepository services organization, EPL Archives, Inc. The financial terms of the deal remain undisclosed.

EPL Archives provides its customers with archive sample, document storage and ancillary services. It aids the customers across the entire regulated product research, development and commercialization lifecycle.

Given that EPL Archives is the trusted partner to the majority of the world's largest pharmaceutical customers, including many existing VWR customers, the latter is highly optimistic about the acquisition.

According to VWR, EPL Archives’ portfolio of services will greatly complement the company’s current service offering, as part of VWRCATALYST. It will allow VWR to ensure compliant storage of research, manufacturing and clinical trial materials.

In this regard we note that, VWR offers its customers an increasing array of value-added services marketed under the VWRCATALYST brand, allowing them to continue outsourcing non-core functions instead of focusing on their own competitive imperatives. Moving forward, the company plans to take necessary steps to continue enhancing customer intimacy, leverage the relative strength of supplier base and increase the use of unique IT capabilities.

The company has successfully maintained a diverse and stable customer base. It centrally manages and actively collaborates with its largest global customers and provides them value-added services, optimize the efficiency of their research, production and procurement activities. It also supports them with dedicated on-site professionals and technicians. Additionally, it manages relationships with regional customers on a local basis, with focus on particular customer segment-specific needs. The latest acquisition of EPL Archives is expected to help the company improve its standards of customer service.

For the last one month, VWR has been trading below the Zacks categorized Medical - Dental Supplies industry. Per the last share price movement, overall the company lost 3.43%, wider than the 0.3% decline of the broader industry, over this period.

Zacks Rank & Key Picks

VWR currently has a Zacks Rank #3 (Hold).

Better-ranked stocks in the medical product sector include Inogen, Inc. INGN, Bovie Medical Corporation BVX and ResMed, Inc. RMD. While Inogen sports a Zacks Rank #1 (Strong Buy), Bovie Medical and ResMed carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Inogen gained 85.1% in the last one year compared with the S&P 500’s gain of 15.2%. The company has a stellar four-quarter positive average earnings surprise of over 49.08%.

Bovie Medical surged 55.9% in the last one year compared with the S&P 500. It has a four-quarter positive average earnings surprise of 28.7%.

ResMed gained over 27.4% in the past one year, better than the S&P 500 mark. It also has a trailing positive average earnings surprise of 0.31%.

Zacks' Top 10 Stocks for 2017

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017? Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Inogen, Inc (INGN): Free Stock Analysis Report
 
ResMed Inc. (RMD): Free Stock Analysis Report
 
Bovie Medical Corporation (BVX): Free Stock Analysis Report
 
VWR Corporation (VWR): Free Stock Analysis Report
 
To read this article on Zacks.com click here.